Stanworth and colleagues have explored the relation between blood loss and mortality in trauma patients in a study stimulated by the changing approach to early trauma management [1] . Th e traditional approach advocates packed red blood cell (PRBC) transfusions and early coagulation testing in the hospital laboratory using assays such as the prothrombin time ratio, the activated partial thromboplastin time ratio, and platelet concentration. Transfusion of fresh frozen plasma, platelets, and sometimes cryoprecipitate was based on results that may be delayed for 60 minutes following sampling. Current guidelines recommend transfusion when prothrombin time ratio or activated partial thromboplastin time ratio >1.5, platelet count <50 × 10 9 /l, or fi brinogen level <1.5 to 2.0 g/l [2] , or after a certain proportion of the circulating volume is lost. Th is approach is inherently reactive rather than proactive and is at risk of closing the door after the horse has bolted. Our increasing understanding that shock and hypoperfusion can initiate infl ammation, which is closely linked to coagulation, creates biological plausibility that the traditional approach may not be best for injured patients.
Up to one-quarter of trauma patients have deranged coagulation on arrival in the emergency department [3] , which is more severe with greater injury severity [3] , acidosis and shock [4] , and is associated with higher PRBC use and mortality [5] . Th is has led to the new concept of haemostatic resuscitation, which advocates point-of-care coagulation testing, higher ratios of fresh frozen plasma and platelets to PRBC, fresh whole blood where available, minimal crystalloid, and early consideration of cryoprecipitate, fi brinogen, activated recombinant factor VII and tranexamic acid [5] [6] [7] [8] [9] [10] . Evidence from cohort studies suggests these interventions are associated with increased survival [7] [8] [9] [10] . War in Iraq and Afghanistan has accelerated this area of research, and further high-quality evidence for military and civilian settings is highly desirable.
Because haemostatic resuscitation aims to hit the problem hard and early, the technique raises several challenges -especially the logistics of providing blood products quickly and safely. Perhaps most challenging is quickly recog nising patients in whom early haemostatic resuscitation is indicated. Trauma patients have a wide range of injury severity, meaning fl uid requirements range from nothing to massive transfusion. Unnecessary transfusion will drain systems of blood products in limited supply, and will increase the risk of transfusion complications.
Stanworth and colleagues have addressed this issue by analysing pooled data from trauma registries in fi ve countries in Europe and North America [1] . Th ey asked two questions: fi rst, is there a threshold eff ect in PRBC use on hospital mortality? Second, can clinical and laboratory parameters available soon after arrival in the emergency department predict who will go on to require massive PRBC transfusion? If a threshold value was found, this might be a useful way of triaging patients, whereas predictive early parameters might be used as a diagnostic test to trigger major haemorrhage protocols and the use of haemostatic resuscitation.
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Using complex statistical modelling methods, the authors found a clear relationship between the number of PRBCs transfused in the fi rst 24 hours and death rates, but no threshold eff ect. Th is observation suggests we should not use arbitrary thresholds of blood loss or blood product use in conceptualising the risk of death, but should acknowledge that all increments represent progres sive increased risk. Th e external validity of the fi ndings needs to acknowledge the fact that the centres involved were well established with high levels of expertise in trauma management, and the relationship might be diff erent in other healthcare organisations. Th e many factors that infl uence trauma outcomes also mean that eff ect modi fi ers could alter the relationship between PRBC trans fusion and mortality. Th e authors provide compelling evi dence that with modern trauma care there is no obvious ceiling eff ect, however, and they emphasise the biological plausibility of using ongoing PRBC requirement as an index of mortality risk.
Despite the lack of threshold eff ect, the authors developed a model to predict massive PRBC transfusion using receipt of at least 10 PRBC units to defi ne massive transfusion. Potential predictor variables were mathemati cally transformed to optimise the fi tting of the model. Although this transformation improved the mathe matics of the model, clinicians are left somewhat perplexed in interpreting the eff ect on transfusion risk of a unit change in, for example, the reciprocal of the natural log of prothrombin time squared! In the model, admission systolic blood pressure, base defi cit, and prothrombin time had strongest association with receiving massive transfusion. Th ese associated parameters are not new, but confi rm what is already known. Including the prothrombin time in a model would limit the value of the score due to the delay in laboratory processing of these samples. When sensitivity in the model was set at 90%, a clinically useful cut-off point, the specifi city was only 50%, correctly classifying only 58% of patients. Th is means that if this score was used to initiate a major haemorrhage protocol and/or haemostatic resusci tation with PRBCs, fresh frozen plasma, and platelets, this would lead to an inappropriate activation on 50% of occasions (based on the 10 PRBC unit cut-off point). On one hand this might be considered an in appropriate use of blood products, but if this method reduced mortality, complications or illness cost -espe cially given the relatively linear relationship between PRBC transfusion and death shown in the fi rst model -it might be considered clinically eff ective and cost-eff ective. Highquality clinical trials of haemostatic resuscitation therapy may help us answer this question.
It would be interesting to compare the performance of this predictive model with other published trauma scores, such as the Trauma Associated Severe Hemor rhage score [11] or the Assessment of Blood Consump tion score [12] , which only used parameters available within the fi rst 15 to 20 minutes of arrival in the emer gency department. Th e Trauma Associated Severe Hemor rhage score correctly classifi ed 89% of cases requiring massive transfusion, and the Assessment of Blood Con sump tion score 85%. Th ese scores were developed in smaller cohorts, however, and whether this performance can be replicated in international cohorts remains to be seen.
Where does this leave us? Th e recent CRASH-2 trial of tranexamic acid in trauma has shown that simple cheap interventions which modify coagulation can improve survival in trauma patients [10] . Clarifying the further impact of more complex and expensive strategies is therefore clearly warranted, because any reduction in coagulopathy and/or PRBC transfusion in this setting is likely to modify outcome. Despite the large databases and complex statistical modelling, Stanworth and colleagues have not provided any new predictors for when to intervene. We therefore need to continue to search for better predictors that could be available within minutes of presentation, perhaps based on thromboelastography or individual factor levels. Until then, as is usually the case in critical care, emphasis should be placed on early assessment and continual reassessment by experienced clinicians working in an organisation capable of delivering therapies quickly and eff ectively.
